Novartis (NYSE:NVS) said today that a committee for the European Medicines Agency has recommended that the regulatory agency approve Aimovig, a self-administered drug designed to prevent migraines in adults who have at least four migraine days each month.
The drug is the first of a new class of medicines, called CGRP inhibitors. It’s a monoclonal antibody that blocks the receptor for a protein that is linked to migraine pain, known as the calcitonin gene-related peptide. Just last month Aimovig, developed by Amgen (NSDQ:AMGN), won FDA approval in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post EMA committee recommends approval for migraine prevention drug appeared first on MassDevice.
from MassDevice https://ift.tt/2soRFLr
Cap comentari:
Publica un comentari a l'entrada